First Artificial Iris Gets FDA Approval
Author: U.S. Food and Drug Administration (FDA)
Published: 2018/06/11 - Updated: 2019/04/30
Topic: Disability Visual Aids (Publications Database)
Page Content: Synopsis Introduction Main Item
Synopsis: U.S. FDA approves a prosthetic iris a surgically implanted device to treat adults and children whose iris is missing or damaged due to a congenital condition called aniridia or other damage to the eye. The FDA grants approval of the CustomFlex Artificial Iris to Clinical Research Consultants, Inc. U.S. Food and Drug Administration recently approved the first stand-alone prosthetic iris in the United States.
Introduction
The U.S. Food and Drug Administration recently approved the first stand-alone prosthetic iris in the United States, a surgically implanted device to treat adults and children whose iris (the colored part of the eye around the pupil) is completely missing or damaged due to a congenital condition called aniridia or other damage to the eye.
Main Item
"Patients with iris defects may experience severe vision problems, as well as dissatisfaction with the appearance of their eye," said Malvina Eydelman, M.D., director of the Division of Ophthalmic, and Ear, Nose and Throat Devices at the FDA's Center for Devices and Radiological Health. "Today's approval of the first artificial iris provides a novel method to treat iris defects that reduces sensitivity to bright light and glare. It also improves the cosmetic appearance of the eye in patients with aniridia."
Congenital aniridia is a rare genetic disorder in which the iris is completely or partially absent.
It affects approximately 1 in 50,000 to 100,000 people in the U.S. The iris controls the amount of light entering the eye, and those with aniridia have sensitivity to light and other severe vision problems. In addition to congenital aniridia, the CustomFlex Artificial Iris is indicated to treat iris defects due to other reasons or conditions, such as albinism, traumatic injury or surgical removal due to melanoma.
The CustomFlex Artificial Iris is made of thin, foldable medical-grade silicone and is custom-sized and colored for each individual patient.
A surgeon makes a small incision, inserts the device under the incision, unfolds it and smooths out the edges using surgical instruments. The prosthetic iris is held in place by the anatomical structures of the eye or, if needed, by sutures.
The safety and effectiveness of the CustomFlex Artificial Iris was demonstrated primarily in a non-randomized clinical trial of 389 adult and pediatric patients with aniridia or other iris defects. The study measured patients' self-reported decrease in severe sensitivity to light and glare post-procedure, health-related quality of life, and satisfaction with the cosmetic improvement or appearance of the prosthesis. More than 70 percent of patients reported significant decreases in light sensitivity and glare as well as an improvement in health-related quality of life following the procedure. In addition, 94 percent of patients were satisfied with the artificial iris' appearance.
The study found low rates of adverse events associated with the device or the surgical procedure.
In the study, complications associated with the use of the CustomFlex Artificial Iris device included: device movement or dislocation, strands of device fiber in the eye, increased intraocular pressure, inflammation of the iris (iritis), adhesion of the iris to the cornea or lens (synechiae) and the need for secondary surgery to reposition, remove or replace the device. Complications associated with the surgical procedure included: increased intraocular pressure, blood leakage in the eye, swelling of the center of the retina (cystoid macular edema), secondary surgery, corneal swelling, iritis, and retinal detachment.
The CustomFlex Artificial Iris is contraindicated, or should not be used, in eyes with any of the following conditions:
- uncontrolled or severe chronic inflammation (uveitis),
- abnormally small eye size (microphthalmus),
- untreated retinal detachment,
- untreated chronic glaucoma,
- cataract caused by rubella virus,
- abnormal blood vessels on the iris (rubeosis),
- certain kinds of damaged blood vessels in the retina,
- intraocular infections.
- It is also contraindicated for patients who are pregnant.
The CustomFlex Artificial Iris was approved through a premarket approval application (PMA), which is the most stringent type of device marketing application and generally required for high-risk devices. A PMA approval is primarily based on a determination by the FDA that the PMA contains sufficient valid scientific evidence that provides reasonable assurance that the device is safe and effective for its intended uses.
CustomFlex Artificial Iris was granted Breakthrough Device designation, meaning the FDA provided intensive interaction and guidance to the company on efficient device development, to expedite evidence generation and the agency's review of the device. To qualify for such designation, a device must provide for more effective treatment or diagnosis of a life-threatening or irreversibly debilitating disease or condition, and meet one of the following criteria: the device must represent a breakthrough technology; there must be no approved or cleared alternatives; the device must offer significant advantages over existing approved or cleared alternatives; or the availability of the device is in the best interest of patients.
The FDA granted approval of the CustomFlex Artificial Iris to Clinical Research Consultants, Inc.
Attribution/Source(s):
This quality-reviewed publication was selected for publishing by the editors of Disabled World due to its significant relevance to the disability community. Originally authored by U.S. Food and Drug Administration (FDA), and published on 2018/06/11 (Edit Update: 2019/04/30), the content may have been edited for style, clarity, or brevity. For further details or clarifications, U.S. Food and Drug Administration (FDA) can be contacted at fda.gov. NOTE: Disabled World does not provide any warranties or endorsements related to this article.
Explore Similar Topics
1 - Revolutionary Vision Therapy: AmblyoPlay Unveils Peripheral Sight Enhancer - AmblyoPlay launches Active Peripheral Stimulation (APS) intended to advance treatment of peripheral vision deficiencies and improve effectiveness of home-based vision therapy.
2 - WorldScribe: Real-Time Surrounding Descriptions for the Visually Impaired - A world of color and texture could soon become more accessible to people who are blind or have low vision through new software called WorldScribe.
3 - Tactile Lithophane Makes Scientific Data Accessible to Students With Blindness - Tactile learning device makes science accessible to students with blindness or low vision (BLV) opens possibility of transfer of scientific data or images for sighted students into functional formats for students with blindness.
Complete Publications Database
Page Information, Citing and Disclaimer
Disabled World is a comprehensive online resource that provides information and news related to disabilities, assistive technologies, and accessibility issues. Founded in 2004 our website covers a wide range of topics, including disability rights, healthcare, education, employment, and independent living, with the goal of supporting the disability community and their families.
Cite This Page (APA): U.S. Food and Drug Administration (FDA). (2018, June 11 - Last revised: 2019, April 30). First Artificial Iris Gets FDA Approval. Disabled World. Retrieved November 7, 2024 from www.disabled-world.com/assistivedevices/visual/iris.php
Permalink: <a href="https://www.disabled-world.com/assistivedevices/visual/iris.php">First Artificial Iris Gets FDA Approval</a>: U.S. FDA approves a prosthetic iris a surgically implanted device to treat adults and children whose iris is missing or damaged due to a congenital condition called aniridia or other damage to the eye.
Disabled World provides general information only. Materials presented are never meant to substitute for qualified medical care. Any 3rd party offering or advertising does not constitute an endorsement.